{
    "2020-04-06": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Alnylam, Dicerna Join Forces to Take on Arrowhead",
                "features": {
                    "keywords": [
                        "Alnylam",
                        "Dicerna",
                        "Arrowhead",
                        "partnership"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Another Drug to Fight Coronavirus & 3 Picks",
                "features": {
                    "keywords": [
                        "drug",
                        "coronavirus",
                        "picks"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Why the Earnings Surprise Streak Could Continue for Lilly (LLY)",
                "features": {
                    "keywords": [
                        "earnings",
                        "surprise",
                        "Lilly"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck",
                "features": {
                    "keywords": [
                        "Zacks",
                        "analyst",
                        "J&J",
                        "Sanofi",
                        "AstraZeneca",
                        "Lilly",
                        "Merck"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}